ClinicalThought

Share

Program Content

Activities

  • Optimizing Switching ART
    Switching ART in Patients With Prior Resistance
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 17, 2022

    Expires: October 16, 2023

    View Activity
  • Using New Drugs Earlier
    Are People With Multidrug-Resistant HIV and Limited Treatment Options Receiving the New Drugs Too Late?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 17, 2022

    Expires: November 16, 2023

    View Activity
  • LA Options for HTE Patients
    New Long-Acting Options for Heavily Treatment–Experienced People With HIV-1
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 05, 2023

    Expires: January 04, 2024

    View Activity
  • Proviral DNA Resistance Testing
    Proviral DNA Resistance Testing: Uses and Limitations When Switching ART
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 06, 2023

    Expires: February 05, 2024

    View Activity

Faculty

cover img faculity

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

cover img faculity

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP

Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

cover img faculity

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

cover img faculity

Paul E. Sax, MD

Professor of Medicine 
Harvard Medical School
Clinical Director 
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital 
Boston, Massachusetts 

Provided by

ProCE Banner

Supporters

Gilead Sciences, Inc.

ViiV Healthcare